Treatment of Infective Endocarditis Due to Methicillin-Susceptible Staphylococci

Infective endocarditis caused by methicillin-susceptible staphylococci is a well-defined clinical scenario in which pathogen susceptibility directly determines the antibiotic strategy. Both native valve endocarditis (NVE) and prosthetic valve endocarditis (PVE) are covered, each with a distinct recommended approach.

Clinical Scenario

Infective endocarditis due to methicillin-susceptible staphylococci — spanning native valve endocarditis (NVE) and prosthetic valve endocarditis (PVE).

Treatment Approach

Beta-lactam antibiotic therapy is the cornerstone of management in this setting. The regimen differs meaningfully between NVE and PVE: prosthetic valve cases involve a more complex combination approach with a longer treatment course. Complete agent selection, dosing, and duration are available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

In patients with NVE due to methicillin-susceptible staphylococci, (flu)cloxacillin or cefazolin is recommended for 4–6 weeks using the following doses:
In patients with PVE due to methicillin-susceptible staphylococci, (flu)cloxacillin or cefazolin with rifampin for at least 6 weeks and gentamicin for 2 weeks is recommended using the following doses:

DOI: 10.1093/eurheartj/ehad193

View source ↗